Blog
RSS FeedPosted by Michael Wonder on 21 Jun 2023
Imbruvica is included in the high-cost protection with a changed benefit limitation
19 June 2023 - Ibrutinib (Imbruvica)140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment ...
Posted by Michael Wonder on 30 Apr 2020
Health economic assessment of Keytruda in head and neck cancer
29 April 2020 - TLV has developed a health economic knowledge base for the regions of the drug Keytruda (pembrolizumab). ...